All In Biotech

Drug Trial Radar · NCT07199413

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 15, 2026

Primary completion

Apr 1, 2029

Study completion Apr 1, 2029

Sponsor

Lead sponsor
Medical College of WisconsinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-center, phase 1 basket trial that will evaluate the safety and feasibility of administering SV-BR-1-GM in combination with pembrolizumab to solid tumor oncology patients over nine cycles.

Conditions

  • Brain Metastases
  • Leptomeningeal Metastasis

Interventions

  • SV-BR-1-GM VaccineBiological

    \~20 X 10\^6 cells across 4 injection sites

  • CyclophosphamideDrug

    300 mg/m\^2 Intravenous

  • PembrolizumabDrug

    200 mg/m\^2 Intravenous

  • InterferonDrug

    0.18 mcg subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Grade 3 or higher adverse eventsTime frame: 30 days after the beginning of study therapy, 9 months after the beginning of study therapy
  2. Study therapy durationTime frame: 6 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.